July 27, 2018 | David Carlson
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.
Read More
Tags: Commercial Contracting, Managed Markets, Market Access, Orphan Drugs, Payer Contract Strategy, Rare Disease
March 21, 2017 | Brandon Underwood
Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.
Read More
Tags: benchmark report, data confidence, patient journey, Specialty Pharmacy
June 2, 2016 | Sunay Shah
In my last post, I explored how IntegriChain Scorecard Analytics can be used to validate whether the implementation of Distribution Service Agreements (DSAs) drives channel performance. In this post, we will deep dive with a step-by-step approach outlining how Scorecard Analytics can be leverage to optimize changes to DSAs. First, let’s look at the metrics. DSA metrics come in two basic flavors – performance and data transmission The performance metrics are typically composed of a service level metric, purchase stability (or demand variability) metric, and an inventory level metric. The data transmission metrics are typically composed of data delivery timeliness, completeness, and […]
Read More
Tags: analytics, DSAs, metrics, Scorecard
May 27, 2016 | Colleen Hallett
The Asembia (formerly known as Armada) Specialty Pharmacy Summit is fast becoming the pharmaceutical industry’s most important meeting. This year’s Las Vegas show boasted a record attendance of nearly 5,000 pharmaceutical manufacturers, specialty pharmacies, payers, and solution vendors. As new therapies trend more and more towards high price, niche, or patient-tailored treatments often requiring special handling, this surge of interest in all things specialty pharmacy is no surprise. The enormous rise in specialty brand launches has changed the traditional channel distribution model. Life sciences distribution channels have become much more complicated, and this has led to an increase in the number […]
Read More
April 6, 2016 | Sunay Shah
Distribution Service Agreements (DSAs) have continued to evolve over recent years especially as they relate to how they evaluate channel performance. For the most part, manufacturers structure the agreements to ensure trade partners effectively and efficiently fulfill downstream orders, manage volatility of orders, maintain appropriate inventory level (as defined by manufacturer), and transmit data to manufacturers. As the industry matures in how DSAs are structured, we are seeing trends of new concepts such as misses being incorporated into agreements. However, what is very interesting is how much the industry has validated the efficacy of DSAs. Even as the agreements are […]
Read More
Tags: distribution service agreements, DSA, pharma channel performance, pharma DSA management
March 2, 2016 | Dave Weiss
By now, government price departments are well underway towards implementing the Final Average Manufacturer Price (AMP) Rule recently issued by the Center of Medicare and Medicaid Services (CMS). AMP is the average manufacturer price paid by retail community pharmacies (RCP). One of the key provisions of the sub-regulatory guidance is related to “5i” drugs (i.e., infused, injected, implanted, inhaled, or instilled drugs) that are drugs that are “not generally dispensed“ (NGD) in retail pharmacies but rather at infusion centers, specialty pharmacies, and so on. Even though 5i drugs are not sold into retail, they still require an AMP for other […]
Read More
Tags: 5i drugs, 867 data, AMP rule, retail community pharmacies
March 1, 2016 | Kevin Leininger
Today we announced an equity partnership with Accel-KKR (AKKR) that is very exciting both for IntegriChain and our customers. Both IntegriChain and AKKR share a singular vision to service underserved constituencies in the life sciences industry. Life sciences companies are facing a rapidly evolving marketplace driven by changes across the entire healthcare ecosystem from providers to payers and distribution platforms. Navigating this requires life sciences companies to completely rethink the way they advance and support patient access. The days of primary care physicians and retail pharmacies serving branded, pill-based prescription products shipped once per week from wholesalers across the US […]
Read More
Tags: AKKR, equity partnership
February 25, 2016 | Miguel Guerreiro
Drexel University’s College of Computing & Informatics hosted its fourth Philly CODEFEST, a two-day coding competition to transform data into real-world solutions. IntegriChain was a huge part of the event by providing judges and mentors and by hosting a workshop to talk to the students about what technology companies are looking for in co-ops and employees. This is just another instance of our continued effort to promote Philadelphia-area technology, which is really starting to expand in the region. We would like to congratulate everyone who won a prize including team Good Civilianship, who won the Grand Prize, the Student Grand Prize, and […]
Read More
Tags: coding, hackathon, Philadelphia, software engineering
January 29, 2016 | Sunay Shah
Everywhere you look, data is being collected and stored in an electronic format. From electronic medical records to the Internet of things, data collection is omnipresent; however, trying to figure out how to extract the maximum value from all of the collected data is a continuous process. Most industries–including consumer marketing, finance, healthcare, and technology–are seeing a revolution in how they analyze data as the amount of data they have at their disposal continues to increase by orders of magnitude. So much so that overall, 90% of the world’s data has been collected in the past two years.* Focusing on […]
Read More
Tags: analytics, data science, healthcare channel data, visualization
December 16, 2015 | Dave Weiss
While we applaud the Health Resources and Services Administration (HRSA) for its efforts to create more transparency in the 340B program through its proposed guidance and program integrity initiative, a quick inspection of the 2015 audit results posted on the Office of Pharmacy Affairs (OPA) website is deeply concerning. As part of this report, HRSA audited 137 covered entities in 2015, which was a 30% increase above 2014. If the results are extrapolated to the universe of 30,000+ covered entities (and their associated contract pharmacies) then the level of potential abuse is far worse than even its harshest critics could […]
Read More
Tags: 340B, chargebacks
